Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Moderate Buy” by Brokerages

Xencor, Inc. (NASDAQ:XNCR) has received an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $35.71.

Several equities analysts have commented on XNCR shares. Mizuho cut their price target on Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a report on Monday, January 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $32.00 price target on shares of Xencor in a report on Wednesday, February 28th. StockNews.com raised Xencor from a “sell” rating to a “hold” rating in a report on Saturday, March 9th. Piper Sandler reaffirmed a “neutral” rating and issued a $24.00 price target (down previously from $37.00) on shares of Xencor in a report on Wednesday, February 28th. Finally, BMO Capital Markets dropped their target price on Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th.

Xencor Stock Performance

NASDAQ:XNCR opened at $20.11 on Tuesday. The firm’s 50-day moving average is $22.24 and its 200-day moving average is $20.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.36 and a current ratio of 7.36. Xencor has a 52-week low of $16.49 and a 52-week high of $30.21.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.67). The firm had revenue of $44.70 million for the quarter, compared to the consensus estimate of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. The company’s revenue was up 106.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. As a group, analysts forecast that Xencor will post -3.25 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Kurt A. Gustafson sold 14,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $23.18, for a total transaction of $324,520.00. Following the sale, the director now directly owns 6,007 shares in the company, valued at approximately $139,242.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Kurt A. Gustafson sold 14,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $23.18, for a total transaction of $324,520.00. Following the sale, the director now directly owns 6,007 shares in the company, valued at approximately $139,242.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP John R. Desjarlais sold 1,280 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $23.50, for a total value of $30,080.00. Following the sale, the vice president now owns 186,433 shares in the company, valued at $4,381,175.50. The disclosure for this sale can be found here. Insiders have sold a total of 101,351 shares of company stock worth $2,152,417 in the last three months. Insiders own 4.97% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of XNCR. CWM LLC boosted its position in Xencor by 498.7% in the 4th quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,147 shares during the last quarter. Parallel Advisors LLC boosted its position in Xencor by 303.9% in the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,015 shares during the last quarter. BluePath Capital Management LLC bought a new position in Xencor in the 3rd quarter valued at $31,000. China Universal Asset Management Co. Ltd. boosted its position in Xencor by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 756 shares during the last quarter. Finally, Signaturefd LLC boosted its position in Xencor by 367.7% in the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,151 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.